Keros announces positive Phase 1 results for KER-065; plans Phase 2 in DMD in Q1 2026

Keros Therapeutics, Inc.

KER-065 generally well-tolerated; no serious adverse events or dose-limiting toxicities reported.
Evidence of activin inhibition: increases in BSAP, adiponectin, and bone density; decreases in CTX, leptin, and fat mass.
Body composition changes included increased muscle mass and reduced fat mass consistent with activin inhibition.
Company expects to initiate Phase 2 trial in Duchenne muscular dystrophy in Q1 2026 after regulatory engagement.
Phase 1 data cut-off Feb 6, 2025; multiple ascending dose period through Day 85 completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.